Sarah Marie Dermody

Dr. Sarah Marie Dermody

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2023 in Cancer
Verified
Journal Article
Open access
CHCatherine T. Haring
Catherine T. Haring
LKLulia A. Kana
Lulia A. Kana
SDSarah Marie Dermody
Sarah Marie Dermody
CBCollin Brummel
Collin Brummel
JMJonathan B. McHugh
Jonathan B. McHugh
PSPaul L. Swiecicki
Paul L. Swiecicki
Background: Development of evidence‐based post‐treatment surveillance guidelines in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) is limited by comprehensive documentation of patterns of recurrence and metastatic spread.Methods: A retrospective analysis of patients diagnosed with R/M HNSCC at a National Cancer Institute‐designated cancer center between 1998– 2019 was performed (n = 447). Univariate and multivariate analysis identified patterns of recurrence and predictors of survival.Results: Median overall survival (mOS) improved over time (6.7 months in 1998–2007 to 11.8 months in 2008–2019, p = .006). Predictors of worse mOS included human papillomavirus (HPV) negativity (hazard ratio [HR], 1.8; 95% confidence interval [CI], 1.2–2.6), high neutrophil/lymphocyte ratio (HR, 2.1 [1.4–3.0], disease‐free interval (DFI) ≤6 months (HR, 1.4 [1.02–2.0]), and poor performance status (Eastern Cooperative Oncology Group, ≥2; HR, 1.91.1–3.4). In this cohort, 50.6% of recurrences occurred within 6 months of treatment completion, 72.5% occurred within 1 year, and 88.6% occurred within 2 years. Metachronous distant metastases were more likely to occur in patients with HPV‐positive disease (odds ratio [OR], 2.3 [1.4–4.0]), DFI >6 months (OR, 2.4 [1.5–4.0]), and body mass index ≥30 (OR, 2.3 [1.1–4.8]). Oligometastatic disease treated with local ablative therapy was associated with improved survival over polymetastatic disease (HR, 0.36; 95% CI, 0.24–0.55).Conclusion: These data regarding patterns of distant metastasis in HNSCC support the clinical utility of early detection of recurrence. Patterns of recurrence in this population can be used to inform individualized surveillance programs as well as to risk‐stratify eligible patients for clinical trials.Plain Language Summary: After treatment for head and neck cancer (HNC), patients are at risk of recurrence at prior sites of disease or at distant sites in the body. This study includes a large group of patients with recurrent or metastatic HNC and examines factors associated with survival outcomes and recurrence patterns. Patients with human papillomavirus (HPV)‐positive HNC have good survival outcomes, but if they recur, this may be in distant regions of the body and may occur later than HPV‐negative patients. These data argue for personalized follow‐up schedules for patients with HNC, perhaps incorporating imaging studies or novel blood tests.

1 October 2016 in International Journal of Pediatric Otorhinolaryngology
Verified
Journal Article
Closed access
SDSarah Marie Dermody
Sarah Marie Dermody
AWAndrew Walls
Andrew Walls
EHEarl H. Harley
Earl H. Harley

15 February 2024 in JCI Insight
Verified
Journal Article
Open access
PDF file
CBChandan Bhambhani
Chandan Bhambhani
QKQing Kang
Qing Kang
DHDaniel H. Hovelson
Daniel H. Hovelson
ESErin Sandford
Erin Sandford
MOMary Olesnavich
Mary Olesnavich
MTMuneesh Tewari
Muneesh Tewari
BACKGROUND: Transrenal cell-free tumor DNA (TR-ctDNA), which transits from the bloodstream into urine, has the potential to enable noninvasive cancer detection for a wide variety of nonurologic cancer types. Methods: Using whole-genome sequencing, we discovered that urine TR-ctDNA fragments across multiple cancer types are predominantly ultrashort (<50 bp) and, therefore, likely to be missed by conventional ctDNA assays. We developed an ultrashort droplet digital PCR assay to detect TR-ctDNA originating from HPV-associated oropharyngeal squamous cell carcinoma (HPV + OPSCC) and confirmed that assaying ultrashort DNA is critical for sensitive cancer detection from urine samples. Results: TR-ctDNA was concordant with plasma ctDNA for cancer detection in patients with HPV + OPSCC. As proof of concept for using urine TR-ctDNA for posttreatment surveillance, in a small longitudinal case series, TR-ctDNA showed promise for noninvasive detection of recurrence of HPV + OPSCC. Conclusion: Our data indicate that focusing on ultrashort fragments of TR-ctDNA will be important for realizing the full potential of urine-based cancer diagnostics. This has implications for urine-based detection of a wide variety of cancer types and for facilitating access to care through at-home specimen collections. Funding: NIH grants R33 CA229023, R21 CA225493; NIH/National Cancer Institute grants U01 CA183848, R01 CA184153, and P30CA046592; American Cancer Society RSG-18-062-01-TBG; American Cancer Society Mission Boost grant MBGI-22-056-01-MBG; and the A. Alfred Taubman Medical Research Institute.

9 October 2017 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
SRShannon Radomski
Shannon Radomski
SDSarah Marie Dermody
Sarah Marie Dermody
EHEarl H. Harley
Earl H. Harley

1 August 2020 in The American Journal of Surgery
Verified
Journal Article
Closed access
JMJessica H. Maxwell
Jessica H. Maxwell
JRJames A. Randall
James A. Randall
SDSarah Marie Dermody
Sarah Marie Dermody
AHAdnan S. Hussaini
Adnan S. Hussaini
HRHamsini Rao
Hamsini Rao
JLJamie R. Litvack
Jamie R. Litvack

18 April 2017 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
SDSarah Marie Dermody
Sarah Marie Dermody
WGWilliam Gao
William Gao
JMJohnathan D. McGinn
Johnathan D. McGinn
SMSonya Malekzadeh
Sonya Malekzadeh